ARMOR3 SV logo copy


New hormonal medicines have expanded the treatment options available for men with advanced prostate cancer. Unfortunately, not all men benefit from these medicines. For some men, hormonal medicines may only work for a while and then stop working. For others, they may not work at all.  Early research has shown that men who test positive for "AR-V7" are less likely to benefit from Zytiga, or Xtandi, which are the only two approved hormonal medicines for patients whose castrate-resistant prostate cancer (CRPC) has spread. AR-V7 can be found through a simple blood test.  Using blood tests to help choose medicines has improved results in several types of cancer.

The ARMOR3-SV clinical trial is for men with CRPC that is metastatic (has spread beyond the prostate to other parts of the body), who have not yet been treated with chemotherapy or certain oral hormonal medicines, and whose cancer is progressing.  The ARMOR3-SV clinical trial will test whether galeterone, an experimental medicine, is helpful for patients who have a substance in the blood called "AR-V7". The trial will compare galeterone against Xtandi in men who test positive for AR-V7.  Galeterone is the first in a new class of medicines for patients who have AR-V7. Research has shown that metastatic CRPC patients who have AR-V7 may be less likely to benefit from existing hormonal medicines like Xtandi®.  If you have metastatic CRPC, ask your doctor to be tested for AR-V7 to see if you are eligible to participate in the ARMOR3-SV clinical trial of galeterone.
To Learn More Click Here


A clinical research study for patients whose prostate cancer has not spread beyond the prostate is now enrolling. Aragon Pharmaceuticals is seeking men to participate in a clinical trial of an investigational drug for prostate cancer. The purpose of the SPARTAN study is to evaluate the safety and effectiveness of an investigational drug in delaying prostate cancer from spreading beyond the prostate.  This study is enrolling patients with prostate cancer who, despite treatment, have rising blood prostate-specific antigen (PSA) levels.  All participants will continue to receive their current treatment along with either the investigational medication or a placebo.  The selections will be random, and the investigational medication will be given to 2 out of every 3 study participants.
To Learn More Click Here

ERA 223 Study

A clinicial research study for patients with asymptomatica/mildly symptomatic castration resistant prostate cancer and two or more bone metastases.  Bayer HealthCare is seeking men to participate in a research study of radium-223.  The purpose of the ERA 223 trial is to determine if the addition of radium-223 to abiraterone acetate is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as bone fractures or bone pain which needs to be treated with an X-Ray machine.  This study is enrolling pateints with prostate cancer who, despite medical or surgical castration, have rising prostate specific antigen (PSA) levels. Eligible patients must have two or more bone metastases with no visceral, e.g. liver metastases and not have received prior chemotherapy.  Prostate cancer lesions must be asymptomatic or mildly symptomatic.  All patients will receive abiraterone acetate along with either radium-223 or placebo. 
To learn more click here.


A clinical study for men whose PSA is rising, despite having ongoing treatment for prostate cancer and whose cancer has not spread beyond the prostate.  The purpose of this study is for doctors and researchers to evaluate the investigational medication ODM-201.  They want to compare the safety and effectiveness of ODM-201 with that of placebo, which looks like ODM-201, but contains no active ingredients.  The results of this study will provide more information about ODM-201 and whether it could one day be used to potentially treat men with prostate cancer that is at risk of progressing, but has not already spread to other areas of the body. 
To learn more click here.